ABOUT
As the Biotech and Pharma industries progress rapidly, the general expectation of better drugs with less or no toxic side effects and higher efficacy is a legitimate factor fueling innovation.
With naturally derived small molecules targeting multiple pathways, our drug candidates - OBX and OPX can change the paradigm of breast and prostate chemoprevention enhancing health span and lifespan.
With prior evidence of safety and efficacy in human use enabling consistent long term use and increased treatment adherence, OBX and OPX will lead to significant reduction in the risk for breast & prostate cancers compared to current standard of care.
Our unique approach is proactive and preventive, aiming to support and maintain cellular health, avoid and address cellular damage and carcinogenesis.
SCIENTIFIC APPROACH
Innovative chemoprevention solutions addressing large unmet needs and affecting a high percentage of both female and male demographics.
Fundamentally different from the current approach, OBX and OPX are delivering multiple active molecules that simultaneously and comprehensively target carcinogenic pathways at cellular level modulating the microenvironment of hormone driven malignancies.
Unsatisfactory secondary chemoprevention represents the biggest challenge in breast, ovarian and prostate cancer (and other hormone driven solid tumors) survival outcomes, resulting in tumor resistance and relapse.
Current chemotherapy protocols combine 2 or 3 drugs in order to obtain a better result than single targeted approach and delay the inevitable tumor mutations resulting in resistance to administered drugs and the need for additional & stronger drugs.
Today, in spite of huge progress in cancer care, over 50% of breast cancers are relapsing up to 32 years after primary diagnosis, and 20-30% of prostate cancers relapse after 5 years, highlighting the need for on-going secondary chemoprevention without side effects in order to block/inhibit carcinogenesis and enable life long cancer-free status.
According to Cancer research UK "1 in 2 people in the UK will get cancer in their lifetime" while in the US, 1 in 2 women and 1 in 3 men will develop cancer in their lifetime. Increasing cancer incidence requires an urgent need for chemoprevention.
Researchers at EMBL’s European Bioinformatics Institute (EMBL-EBI) and the Francis Crick Institute have discovered that Cancer mutations occur decades before diagnosis.
Our approach is proactive and preventive, both before diagnosis, or when patient is in remission, in order to disrupt and block carcinogenesis and protect cellular health.
We aim to help change these dreadful odds with safe, effective and affordable compositions in order to prolong health span and longevity.
PIPELINE
We are developing several phyto bioactives in different stages of preclinical studies with evidenced POC.
Market for Secondary Chemoprevention: millions of women are not adequately protected in remission due to poor treatment adherence to current generic estrogen depletion SOC drugs - recurrence can occur 10-32 years after BC primary diagnosis in close to 50% of cases.
Market size with IP protection: US, EU, CA, JP. Female demographic >400m.
Recommended daily long-term use in women ages 20-80 at high/average risk.
Standardized research samples and protocol for Pilot Clinical trial available.
OBX can offer superior alternatives to current standard of care, without side effects, enabling long term chemoprevention.
Breast Cancer Therapeutics Market size: USD 28.8 billion in 2022 projected to reach USD 73.68 billion by 2032 with a compound annual growth rate (CAGR) of 9.9%.
Demonstrated significant improvement in multiple sperm parameters in case study, with long term relevance for prostate health and male fertility. Recent studies identified low sperm quality as an early risk marker for prostate cancer. OPX can significantly lower the risk of prostate malignancy development with daily use.
Market size with IP protection: EU
Recommended: Daily long-term use in men 30-80 with family history, African descent, lifestyle.
Standardized research samples and protocol for Pilot Clinical trial available.
Background: Prostate health is crucial to men's health and wellbeing at all ages. 1 in 6 Caucasian men will be diagnosed with prostate cancer, while the risk in men of African descent is 1 in 4. According to the American Urology Association:
- 90% of men between 45-80 suffer from some type of lower Urinary Tract Symptoms (LUTS).
- About half of all men between 51-60 have Benign Prostate Hyperplasia (BPH).
- Up to 90% of men over age 80 have BPH.
Lancet Commission on Prostate Cancer (April 2024): Prostate Cancer cases expected to double from 1.4million 2020 to 2.9 million by 2040- main increase in East Asia.
Due to antimicrobial resistance UTIs have become a serious global health concern leading to an increase in hospitalization and sepsis cases.
Market size with IP protection: UK, US.
Trademarks US, UK & Japan.